Navigation Links
Drug combination shows promise for newly diagnosed blood cancer patients, study finds
Date:12/9/2010

ANN ARBOR, Mich. A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib as a front-line treatment of patients with myeloma, a type of cancer that arises in the plasma cells.

Initial results of the phase I study were presented at the American Society of Hematology Annual Meeting and Exposition.

"This combination treatment appears to deliver everything we expected and more. We have seen no neurotoxicity and fantastic efficacy, the best reported to date," says study author Andrzej Jakubowiak, M.D., Ph.D., director of the multiple myeloma program at the University of Michigan Comprehensive Cancer Center.

The study, which still is accruing participants, has enrolled 31 people to date. All patients responded to this combination, measured by at least a 50 percent reduction of the disease, and the disease was completely or nearly eliminated in a significant portion of patients.

Responses were rapid, and the depth of response continued to improve with additional treatment. Of patients who completed eight cycles of therapy, more than two-thirds achieved a complete response, meaning they showed little or no signs of cancer. These response rates appear to be higher than those achieved by the best current regimens in newly diagnosed multiple myeloma.

After a median follow-up of six months, all patients were alive with no progression of their cancer.

Researchers found that the three-drug combination, called CRd, was well-tolerated, with few serious side effects. Most notably, peripheral neuropathy -- which is marked by numbness or tingling of the fingers and
'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Combination therapy more effective for enlarged prostate
3. Combination Treatment May Help Depressed Alcoholics
4. Researchers find new chemotherapy combination shows promise in endometrial cancer
5. Leeza Gibbons and ZERONA Equals a Winning Combination
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
8. Combination therapy targets stubborn leukemia stem cells
9. Combination treatment regimen not effective against advanced melanoma
10. New combination effective against pancreatic cancer
11. Noninvasive combination technique may reduce number of breast biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Boston, MA (PRWEB) , ... September 02, 2015 ... ... reports covering healthcare innovation and investment, announced the two leaders who will deliver ... Boston on November 3, at the Mandarin Oriental Hotel in Boston. , Larry ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and ... mixed documents that include EOBs, payments, and payment related documents. AD-EOB A/R helps ... to reconcile their billing, with one efficient process and interface,“ stated Rich Caproni, ...
Breaking Medicine News(10 mins):Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... obesity being so much in the center of attention now ... cute, chubby babies might actually be too fat //for their ... crafted message that are coming from several top health groups, ... Control and Prevention and the American Academy of Pediatrics as ...
... to an outbreak of mosquito-borne encephalitis B in China, the ... to the 26 people already killed by the disease. ... infected with the disease and 40 of them have died ... in the first six months of 2006. But the newspaper ...
... a study published in the August issue of the Journal, ... have found //that certain risks factors put people younger than ... The findings were based on the study done on ... of people over 60. ,Peripheral vascular disease ...
... disclosed that a specific variety of adult ... neurons or other// types of tissue depending on the ... ,The researchers found that mesenchymal stem cells, which are ... clues from their local environment, allowing a transformation into ...
... exempting mental health units from the ban on smoking ... in the health of people// suffering mental ailments. Smoking ... premature death in the United Kingdom, with nearly 106,000 ... , ,The Health Act 2006 will make ...
... small study revealed that botox injections can help in healing ... Sherris, professor and chair of the department of otolaryngology at ... He said ” This is the first medication found to ... of Mayo Clinic Proceedings. ,The study was conducted ...
Cached Medicine News:Health News:Chubbiness In Babies Might Not Be A Cute Sign 2Health News:Adult stem cells are sensitive to responses from the environment 2Health News:Smoking Ban should Include Mental Health Units 2
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015  Seeger ... knee implant bellwether trial will commence October 13, 2015. ... 1995 using the 510K fast-track approval program, Zimmer NexGen ... The program only requires that companies provide evidence that ... approved product in order to gain permissions. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Acquire Exclusive Rights to Gastrin Based Therapies Program for ... ... TORONTO, March 13 Eli Lilly,and Company (NYSE: LLY ) ... two companies have entered into a licensing,and collaboration agreement granting Lilly ...
... KANSAS CITY, Mo., March 13 Synbiotics Corporation ... the Food & Drug,Administration (FDA) for the use ... in humans. This represents Synbiotics first foray into ... Synbiotics,initial intent to market this product itself to ...
Cached Medicine Technology:Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 2Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 3Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement 4Synbiotics Corporation Announces Human Submission for FluDetect(R) 2
Inquire...
... K2 / gel tubes are for ... molecular diagnostics and for viral load ... blood remain stable at room temperature ... optimal results, it is recommended to ...
Glass Whole Blood Tube with K3EDTA...
... transglutaminase (tTg) is a ubiquitous enzyme ... Tissue transglutaminase is also the specific ... endomysial antibody immunofluorescence (EMA) tests (Bio-Rad ... IgA and,IgG serologic tests are highly ...
Medicine Products: